A new model of LMP1–MYC interaction in B cell lymphoma

References

• Graham JP, Arcipowski KM, Bishop GA. Differential B-lymphocyte regulation by CD40 and its viral mimic, latent membrane protein 1. Immunol Rev 2010;237:226–248.
   PubMedGoogle Scholar
• Heslop HE. Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas. Hematol Am Soc Hematol Educ Prog 2005:260–266.
   Google Scholar
• Stunz LL, Busch LK, Munroe ME, et al. Expression of the cytoplasmic tail of LMP1 in mice induces hyperactivation of B lymphocytes and disordered lymphoid architecture. Immunity 2004;21:255–266.
   PubMed Web of Science ®Google Scholar
• Rastelli J, Homig-Holzel C, Seagal J, et al. LMP1 signaling can replace CD40 signaling in B cells in vivo and has unique features of inducing class-switch recombination to IgG1. Blood 2008;111: 1448–1455.
   PubMed Web of Science ®Google Scholar
• Kulwichit W, Edwards RH, Davenport EM, et al. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci USA 1998;95:11963–11968.
   PubMed Web of Science ®Google Scholar
• Zhang B, Kracker S, Yasuda T, et al. Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model. Cell 2012;148:739–751.
   PubMed Web of Science ®Google Scholar
• Kraus ZJ, Nakano H, Bishop GA. TRAF5 is a critical mediator of in vitro signals and in vivo functions of LMP1, the viral oncogenic mimic of CD40. Proc Natl Acad Sci USA 2009;106:17140–17145.
   PubMed Web of Science ®Google Scholar
• Slack GW, Gascoyne RD. MYC and aggressive B-cell lymphomas. Adv Anat Pathol 2011;18:219–228.
   PubMed Web of Science ®Google Scholar
• Park SS, Kim JS, Tessarollo L, et al. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. Cancer Res 2005;65:1306–1315.
   PubMed Web of Science ®Google Scholar
• Zhu D, Qi CF, Morse HC 3rd, et al. Deregulated expression of the Myc cellular oncogene drives development of mouse “Burkitt- like” lymphomas from naive B cells. Blood 2005;105:2135–2137.
   PubMed Web of Science ®Google Scholar
• Nawijn MC, Alendar A, Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer 2011;11:23–34.
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim WS, Yun Y, et al. Epstein-Barr virus latent membrane protein 1 increases chemo-resistance of cancer cells via cytoplasmic sequestration of Pim-1. Cell Signal 2010;22:1858–1863.
   PubMed Web of Science ®Google Scholar
• Brown KD, Hostager BS, Bishop GA. Differential signaling and tumor necrosis factor receptor-associated factor (TRAF) degradation mediated by CD40 and the Epstein-Barr virus oncoprotein latent membrane protein 1 (LMP1). J Exp Med 2001;193:943–954.
   PubMed Web of Science ®Google Scholar
• Hostager BS, Haxhinasto SA, Rowland SL, et al. Tumor necrosis factor receptor-associated factor 2 (TRAF2)-deficient B lymphocytes reveal novel roles for TRAF2 in CD40 signaling. J Biol Chem 2003;278:45382–45390.
   PubMed Web of Science ®Google Scholar
• Baccam M, Bishop GA. Membrane-bound CD154, but not CD40-specific antibody, mediates NF-kappaB-independent IL-6 production in B cells. Eur J Immunol 1999;29:3855–3866.
   PubMedGoogle Scholar
• Arcipowski KM, Stunz LL, Graham JP, et al. Molecular mechanisms of TNFR-associated factor 6 (TRAF6) utilization by the oncogenic viral mimic of CD40, latent membrane protein 1 (LMP1). J Biol Chem 2011;286:9948–9955.
   PubMed Web of Science ®Google Scholar
• Bishop GA, Haughton G. Induced differentiation of a transformed clone of Ly-1 + B cells by clonal T cells and antigen. Proc Natl Acad Sci USA 1986;83:7410–7414.
   PubMed Web of Science ®Google Scholar
• Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997; 15:405–431.
   PubMed Web of Science ®Google Scholar
• Leen A, Meij P, Redchenko I, et al. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J Virol 2001;75:8649–8659.
   PubMed Web of Science ®Google Scholar
• Kwon JM, Park YH, Kang JH, et al. The effect of Epstein-Barr virus status on clinical outcome in Hodgkin's lymphoma. Ann Hematol 2006;85:463–468.
   PubMed Web of Science ®Google Scholar
• Young LS, Dawson CW, Eliopoulos AG. The expression and function of Epstein-Barr virus encoded latent genes. Mol Pathol 2000; 53:238–247.
   PubMedGoogle Scholar
• Vrazo AC, Chauchard M, Raab-Traub N, et al. Epstein-Barr virus LMP2A reduces hyperactivation induced by LMP1 to restore normal B cell phenotype in transgenic mice. PLoS Pathogens 2012; 8:e1002662.
   Web of Science ®Google Scholar
• Kim JH, Kim WS, Park C. Epstein-Barr virus latent membrane protein 1 increases genomic instability through Egr-1-mediated up-regulation of activation-induced cytidine deaminase in B-cell lymphoma. Leuk Lymphoma 2013;54:2035–2040.
   PubMed Web of Science ®Google Scholar
• Rutsch S, Neppalli VT, Shin DM, et al. IL-6 and MYC collaborate in plasma cell tumor formation in mice. Blood 2010;115: 1746–1754.
   PubMed Web of Science ®Google Scholar
• Suematsu S, Matsusaka T, Matsuda T, et al. Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc Natl Acad Sci USA 1992;89: 232–235.
   PubMed Web of Science ®Google Scholar
• Mock BA, Hartley J, Le Tissier P, et al. The plasmacytoma resistance gene, Pctr2, delays the onset of tumorigenesis and resides in the telomeric region of chromosome 4. Blood 1997;90: 4092–4098.
   PubMed Web of Science ®Google Scholar
• Zhang K, Kagan D, DuBois W, et al. Mndal, a new interferon-inducible family member, is highly polymorphic, suppresses cell growth, and may modify plasmacytoma susceptibility. Blood 2009; 114:2952–2960.
   PubMed Web of Science ®Google Scholar
• Brault L, Gasser C, Bracher F, et al. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica 2010;95:1004–1015.
   PubMed Web of Science ®Google Scholar
• Pandya J, Walling DM. Epstein-Barr virus latent membrane protein 1 (LMP-1) half-life in epithelial cells is down-regulated by lytic LMP-1. J Virol 2004;78:8404–8410.
   PubMed Web of Science ®Google Scholar
• Zhu N, Ramirez LM, Lee RL, et al. CD40 signaling in B cells regulates the expression of the Pim-1 kinase via the NF-kappa B pathway. J Immunol 2002;168:744–754.
   PubMed Web of Science ®Google Scholar